Orgenesis Announces Virtual 2020 Annual Meeting of Stockholders
November 03 2020 - 3:14PM
Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a
global biotech company working to unlock the full potential of cell
and gene therapies, announced today that due to the public health
impact of the COVID-19 pandemic and to support the health and
well-being of its stockholders, the 2020 Annual Meeting, scheduled
for November 18, 2020 at 10:00 am Eastern Time, will be held in a
virtual format only. An in-person meeting will not be held this
year.
To attend and participate in the Annual Meeting,
stockholders of record as of the close of business on September 21,
2020 may visit the virtual event link provided in their proxy
notice and use the control number received to log into the website.
Stockholders will have the opportunity to vote and ask questions
during the Annual Meeting by following the instructions available
on the meeting website. For stockholders who have already voted, no
action is required. Stockholders may log into the website 15
minutes prior to the meeting start time.
A support line will also be available during the
Annual Meeting should stockholders require assistance. Digital
copies of the Company’s proxy statement and 2019 Annual Report are
available on the Company’s website at www.orgenesis.com, and will
also be available on the webcast.
Whether or not stockholders plan to attend the
Annual Meeting, Orgenesis urges stockholders to select one of the
methods described in the proxy materials to vote and submit their
proxies in advance of the Annual Meeting. The proxy card included
with the proxy materials previously distributed will not be updated
to reflect the change in location and may continue to be used to
vote stockholder shares in connection with the Annual Meeting.
About Orgenesis
Orgenesis is a global biotech company working to
unlock the full potential of cell and gene therapies (CGTs) in an
affordable and accessible format at the point of care. The
Orgenesis POCare Platform is comprised of three enabling
components: a pipeline of licensed POCare
Therapeutics that are processed and produced in closed,
automated POCare Technology systems across a
collaborative POCare Network. Orgenesis identifies
promising new therapies and leverages its POCare Platform to
provide a rapid, globally harmonized pathway for these therapies to
reach and treat large numbers of patients at lowered costs through
efficient, scalable, and decentralized production. The Network
brings together patients, doctors, industry partners, research
institutes and hospitals worldwide to achieve harmonized, regulated
clinical development and production of the therapies. Learn more
about the work Orgenesis is doing at
www.orgenesis.com.
Forward-Looking Statements
Statements contained herein that relate to the
Company’s 2020 annual meeting of stockholders are forward-looking
statements as that term is defined in Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Words or phrases such as “will be,” “will,” “may” or other similar
words or expressions often identify forward-looking statements.
Such statements are based on current expectations only and are
subject to certain risks, uncertainties, and assumptions, many of
which are beyond our control. Among the factors that could cause
the Company’s 2020 annual meeting logistical arrangements to change
include: general business and economic conditions; imposition of
restrictive governmental regulations implemented to address public
health concerns; or operational delays or difficulties because of
the novel coronavirus or similar diseases, or uncertainty regarding
the same. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact for Orgenesis:
Crescendo Communications, LLC Tel:
212-671-1021 ORGS@crescendo-ir.com
Source: Orgenesis Inc.
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From Apr 2024 to May 2024
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From May 2023 to May 2024